XML 37 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segments of Business and Geographic Areas
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas Segments of business and geographic areas
Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two business segments: Innovative Medicine and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.
Sales by segment of business
 Fiscal First Quarter Ended
(Dollars in Millions)March 31,
2024		April 2,
2023		Percent
Change
INNOVATIVE MEDICINE
Immunology
U.S.
$2,4532,4480.2 %
International
1,7941,6647.9 
Worldwide
4,2474,1123.3 
REMICADE
U.S.
266276(3.9)
U.S. Exports
2741(32.7)
International
141170(17.2)
Worldwide
434487(10.9)
SIMPONI / SIMPONI ARIA
U.S.
254271(6.2)
International
29926612.4 
Worldwide
5545373.0 
STELARA
U.S.
1,3961,451(3.8)
International
1,0559936.2 
Worldwide
2,4512,4440.3 
TREMFYA
U.S.
50940625.4 
International
29923427.9 
Worldwide
80864026.3 
OTHER IMMUNOLOGY
U.S.
03*
International
00— 
Worldwide
03*
Infectious Diseases
U.S.
324392(17.4)
International
4971,193(58.4)
Worldwide
8211,586(48.3)
COVID-19 VACCINE
U.S.
00— 
International
25747(96.6)
Worldwide
25747(96.6)
EDURANT / rilpivirine
U.S.
89(10.9)
 Fiscal First Quarter Ended
(Dollars in Millions)March 31,
2024		April 2,
2023		Percent
Change
International
31527116.6 
Worldwide
32328015.7 
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.
314378(16.9)
International
104995.5 
Worldwide
418477(12.3)
OTHER INFECTIOUS DISEASES
U.S.
25(68.8)
International
5277(32.8)
Worldwide
5382(35.1)
Neuroscience
U.S.
1,0549787.8 
International
749826(9.3)
Worldwide
1,8031,8040.0
CONCERTA / methylphenidate
U.S.
4170(41.2)
International
136136(0.1)
Worldwide
177206(14.1)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.
7657137.2 
International
292331(11.8)
Worldwide
1,0561,0441.2 
SPRAVATO
U.S.
19111171.5 
International
342076.1 
Worldwide
22513172.2 
OTHER NEUROSCIENCE
U.S.
5884(31.1)
International
287339(15.5)
Worldwide
345423(18.5)
Oncology
U.S.
2,3831,88926.2 
International
2,4302,2239.3 
Worldwide
4,8144,11217.1 
CARVYKTI
U.S.
1407099.8 
International
162*
Worldwide
15772*
DARZALEX
U.S.
1,4641,19122.9 
 Fiscal First Quarter Ended
(Dollars in Millions)March 31,
2024		April 2,
2023		Percent
Change
International
1,2281,07214.5 
Worldwide
2,6922,26418.9 
ERLEADA
U.S.
28524914.1 
International
40429338.0 
Worldwide
68954227.0 
IMBRUVICA
U.S.
265270(1.5)
International
518557(7.0)
Worldwide
784827(5.2)
TECVAYLI(1)
U.S.
1015776.7 
International
336*
Worldwide
13363*
ZYTIGA / abiraterone acetate
U.S.
916(41.3)
International
172229(24.8)
Worldwide
181245(25.9)
OTHER ONCOLOGY
U.S.
11935*
International
6064(6.1)
Worldwide
1789980.2 
Pulmonary Hypertension
U.S.
76660027.5 
International
2832724.1 
Worldwide
1,04987220.2 
OPSUMIT
U.S.35627330.4 
International1691670.8 
Worldwide52444019.1 
UPTRAVI
U.S.39230429.0 
International765830.7 
Worldwide 46836229.2 
OTHER PULMONARY HYPERTENSION
U.S.
1823(24.6)
International3947(16.9)
Worldwide 5670(19.5)
Cardiovascular / Metabolism / Other
U.S.631715(11.7)
International197212(7.0)
Worldwide829927(10.6)
 Fiscal First Quarter Ended
(Dollars in Millions)March 31,
2024		April 2,
2023		Percent
Change
XARELTO
U.S.518578(10.4)
International——— 
Worldwide518578(10.4)
OTHER
U.S.114137(17.1)
International197212(7.0)
Worldwide311349(11.0)
TOTAL INNOVATIVE MEDICINE  
U.S.7,6127,0238.4 
International5,9506,390(6.9)
Worldwide13,56213,4131.1 
MEDTECH
Cardiovascular(2)
U.S.1,02586318.8 
International78164022.1 
Worldwide1,8061,50320.2 
ELECTROPHYSIOLOGY
U.S.69257121.3 
International65252224.9 
Worldwide1,3441,09223.0 
ABIOMED
U.S.30326415.0 
International676012.4 
Worldwide37132414.5 
OTHER CARDIOVASCULAR(2)
U.S.30283.3 
International62586.9 
Worldwide92875.7 
Orthopaedics
U.S.1,4481,3636.2 
International8928811.3 
Worldwide2,3402,2454.3 
HIPS
U.S.27024112.1 
International1521491.7 
Worldwide4223908.1 
KNEES
U.S.2422266.9 
International16014212.3 
Worldwide4013689.0 
 Fiscal First Quarter Ended
(Dollars in Millions)March 31,
2024		April 2,
2023		Percent
Change
TRAUMA
U.S.5044912.8 
International261267(2.3)
Worldwide7657571.0 
SPINE, SPORTS & OTHER
U.S.4324066.5 
International320323(0.9)
Worldwide7527293.2 
Surgery
U.S.9879751.2 
International1,4291,459(2.0)
Worldwide2,4162,434(0.7)
ADVANCED
U.S.4464440.2 
International641673(4.7)
Worldwide1,0871,118(2.8)
GENERAL
U.S.5425312.1 
International7887850.3 
Worldwide1,3301,3161.0 
Vision
U.S.547558(1.8)
International710743(4.4)
Worldwide1,2581,300(3.3)
CONTACT LENSES / OTHER
U.S.438444(1.4)
International472509(7.4)
Worldwide910953(4.6)
SURGICAL
U.S.110114(3.7)
International2382332.2 
Worldwide3483470.3 
TOTAL MEDTECH  
U.S.4,0083,7596.6 
International3,8133,7222.4 
Worldwide7,8217,4814.5 
WORLDWIDE   
U.S.11,62010,7827.8 
International9,76310,112(3.4)
Worldwide$21,38320,8942.3 %
*    Percentage greater than 100% or not meaningful
(1)Previously included in Other Oncology (2) Previously referred to as Interventional Solutions
Earnings before provision for taxes by segment
 Fiscal First Quarter Ended
(Dollars in Millions)March 31,
2024		April 2,
2023		Percent
Change
Innovative Medicine(1)
$4,9694,40212.9 %
MedTech(2)
1,5201,4097.9 
Segment earnings before provision for taxes6,4895,81111.7 
Less: Expense not allocated to segments (3)
2,7757,098 
Worldwide income (loss) before tax$3,714(1,287)
(1)    Innovative Medicine includes:
•Intangible amortization expense of $0.7 billion in both the fiscal first quarter of 2024 and 2023.
•One-time COVID-19 Vaccine related exit costs of $0.4 billion in the fiscal first quarter of 2023.
•A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2024 and 2023.
(2)    MedTech includes:
•Intangible amortization expense of $0.4 billion in both the fiscal first quarter of 2024 and 2023.
(3)    Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarters of 2024 and 2023 include charges for talc matters of $2.7 billion and $6.9 billion, respectively (See Note 11, Legal Proceedings, for additional details).
Sales by geographic area
 Fiscal First Quarter Ended
(Dollars in Millions)March 31, 2024April 2, 2023Percent
Change
United States$11,62010,7827.8 %
Europe5,1635,590(7.6)
Western Hemisphere, excluding U.S.1,1941,07611.0 
Asia-Pacific, Africa3,4063,446(1.1)
Total$21,38320,8942.3 %